Abstract
Schizophrenia in the pediatric population poses unique challenges and has been associated with poorer prognosis. Early intervention and symptom stability are paramount. There are several antipsychotic medications with U.S. Food and Drug Administration approval, but when treatment resistance occurs, clozapine is an option that has demonstrated superiority in effectiveness. Due to side effect burden and monitoring requirements, clozapine remains an alternative to other pharmacotherapy options that have failed rather than a mainstay of treatment. Clinicians, nurses, family members, and others involved in pediatric mental health care must be knowledgeable about this option and how to maintain safety with its use. [Journal of Psychosocial Nursing and Mental Health Services, 61(2), 6-8.].
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of psychosocial nursing and mental health services
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
